# Abhijit Gadkari

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/abhijit-gadkari/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,028 |
| Field | Dermatology and Skin Diseases |
| h-index | 34 |
| i10-index | 47 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5109415560 |
| Works | 79 |

## Researcher papers

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Atopic dermatitis in the pediatric population](https://scholariq.org/papers/atopic-dermatitis-in-the-pediatric-population/)
- [Unintentional non-adherence to chronic prescription medications: How unintentional is it really?](https://scholariq.org/papers/unintentional-non-adherence-to-chronic-prescription-medications-how/)
- [Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study](https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/)
- [Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey](https://scholariq.org/papers/impact-of-atopic-dermatitis-on-health-related-quality-of-life-and-productivity/)
- [Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-multiple-dupilumab-dose-regimens-after-initial-successful/)
- [Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-monotherapy-in-adults-with-moderate-to-severe/)
- [Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)](https://scholariq.org/papers/dupilumab-therapy-provides-clinically-meaningful-improvement-in-patient-reported/)
- [Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis](https://scholariq.org/papers/treatment-outcomes-associated-with-dupilumab-use-in-patients-with-atopic/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.